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Introduction: Previous studies in humans support the dual‐allergen exposure
hypothesis, and several studies in mouse models have demonstrated that cu-
taneous exposure to disrupted or intact skin can lead to sensitization to peanut.
However, the field lacks definitive evidence that cutaneous exposure leads to
peanut allergy in humans or other primates.
Methods: Peanut extract was applied to the shaved back of the neck of four
male and four female African green monkeys three times per week for 4 weeks.
An oral food challenge (OFC) was performed the following week by gavage of
200mg of peanut protein, and vital signs were monitored for 30minutes post‐
OFC. Blood was collected at baseline, day 11, day 32, and 30minutes post‐OFC.
Total IgE, and peanut‐specific immunoglobulin E (IgE) and immunoglobulin G
(IgG) were quantified in serum collected throughout the 4 weeks. Histamine was
measured in serum collected 30minutes post‐OFC.
Results: Peanut‐specific IgE was undetectable at any time points in any of the
monkeys, and there was no consistent increase in total IgE. During the oral
challenge, none of the monkeys experienced allergic symptoms and histamine
levels did not change. However, seven of the eight monkeys produced
increasing peanut‐specific IgG by day 32, indicating that repeated skin
exposure to peanut is immunogenic.
Conclusions: Skin exposure to peanut did not lead to sensitization in this
study, and monkeys did not experience anaphylaxis upon peanut challenge.
However, monkeys produced increased peanut‐specific IgG throughout peanut
exposure, indicating that repeated skin exposure to peanut is immunogenic.
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1 | INTRODUCTION
Peanut allergy affects an estimated 1% of children in
the United States and the prevalence has increased
over the past two decades.1 A long‐standing observa-
tion by allergists is that children diagnosed with a
peanut allergy react on their first known ingestion,
implying that sensitization to peanut antigens may
have occurred through a nonoral route. There is
mounting evidence supporting the role of allergen ex-
posure through the skin and subsequent development
of peanut allergy. For example, a strong risk factor for
peanut allergy is severe eczema and filaggrin mutations
that lead to disrupted skin barrier function.2,3 In ad-
dition, peanut allergens found in house dust samples
contain biologically active allergens that can cross‐link
immunoglobulin E (IgE) on basophils indicating an
environmental source of allergens.4 The concept of
skin barrier impairment and environmental exposure
to peanut antigens has been investigated in the United
States and the United Kingdom with results indicating
associations of increased risk in children with dis-
rupted skin barrier and dose‐dependent exposure to
peanut as estimated by quantities of allergen in the
house dust.5,6
Another important observation connecting early dietary
introduction of peanut in Israel vs delayed introduction in
the United Kingdom and peanut allergy development was
made approximately 10 years ago. Researchers found a 10‐
fold increased risk for having peanut allergy in the UK
population and attributed the decreased prevalence in Israel
to early oral exposure to peanut.7 These researchers have
since developed the dual‐allergen exposure hypothesis,
which theorizes that tolerance is induced through oral ex-
posure to high quantities of antigen, and sensitization and
subsequent allergy is induced through cutaneous exposure
to low quantities of antigen, before oral exposure during
infancy.6 Specifically, genetically predisposed infants that
are first cutaneously exposed to peanut, before oral con-
sumption, are more likely to develop an allergy. A land-
mark clinical trial titled Learning Early About Peanut
Allergy (LEAP) demonstrated that exposing infants less
than 1 year of age to peanut orally several times per week
significantly reduced the likelihood of developing an allergy
later in childhood, compared to infants who were not orally
ingesting peanuts.8 While all of these studies support the
dual‐allergen exposure hypothesis, the field lacks definitive
evidence that cutaneous exposure leads to peanut allergy in
humans or other primates.
Several studies in mouse models have demonstrated
that cutaneous exposure to disrupted or intact skin can
lead to sensitization to various foods, including peanut.9‐13
A particularly interesting study demonstrated that peanut
itself has adjuvant properties and can induce sensitization
to other food antigens simultaneously applied to the ro-
dent's skin.13 In that study, 1mg of peanut extract in 50 to
100 µL was applied on the skin and left to dry. Cutaneous
exposure was repeated once weekly for 6 weeks, then an
oral peanut challenge was performed 1 week later. We
aimed to determine whether a similar protocol would lead
to sensitization (ie, peanut‐specific IgE in serum) and
allergy (ie, anaphylaxis upon oral peanut challenge) in a
nonhuman primate model.
2 | METHODS
Our study population was 1.2‐ to 1.4‐year‐old African
green monkeys (Chlorocebus aethiops sabaeus) housed at
the Wake Forest School of Medicine that had never in-
gested peanut as part of their diet. Eight monkeys were
enrolled in the study, four females and four males. The
study design is depicted in Figure 1A; the protocol was
approved by the Wake Forest IACUC (protocol # A18‐138)
and complied with the ARRIVE guidelines. A small area
on the back of the neck was shaved using electric clippers
for application of peanut antigens (Figure 1B), to prevent
monkeys from licking or rubbing the application site.
Peanut extract containing all major allergens
was made from a defatted, lightly roasted peanut flour
(Golden Peanut) extracted in phosphate‐buffered saline, as
previously described.14 Glycerol was added to the aqueous
peanut extract to provide viscosity and prevent immediate
runoff from the skin. One milligram of peanut in 200 µL
was applied, and left to dry, three times per week
(Monday, Wednesday, and Friday) for 4 weeks. Blood was
collected by femoral venipuncture at baseline, day 11, and
day 32 under ketamine anesthesia (10mg/kg, in-
tramuscular). An oral food challenge (OFC) was per-
formed, also under ketamine anesthesia, the following
week by gavage of 200mg of peanut extract (10mL of a
20mg/mL solution) and a blood sample was collected
30minutes post‐OFC. Vital signs, including respiration
rate, heart rate, blood pressure, partial pressure of blood
oxygenation, rectal temperature, and observable skin
reactions, were monitored for 30minutes post‐OFC.
Serum was assessed for both total IgE and peanut‐
specific IgE by enzyme‐linked immunosorbent assay
(ELISA). Total IgE was quantified using a kit from Life
Diagnostics whereas peanut‐specific IgE was quantified
with the peanut extract used for skin applications and the
anti‐monkey IgE from the Life Diagnostics kit. Peanut‐
specific immunoglobulin G (IgG) was measured in serum
collected throughout the course of peanut exposure via
ELISA, using peanut extract to coat plates and an anti‐
monkey IgG antibody for detection (Abcam). Histamine
212 | KULIS ET AL.
FIGURE 2 Immunoglobulin production throughout the course of peanut exposure. A, Total IgE in the serum of individual male and
female monkeys. B, Grouped IgE data at days 0 and 32. C, Peanut‐specific IgG in the serum of individual male and female monkeys.
D. Grouped IgG data at days 0 and 32. IgE, immunoglobulin E; IgG, immunoglobulin G. *P< .05
FIGURE 1 Study design.
A, Experimental scheme indicating peanut
exposure regimen, blood collection, and oral
food challenge (OFC). B, Photo of a monkey
with peanut extract applied on the shaved
area on the back of the neck
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levels were measured in serum collected 30minutes post‐
OFC by ELISA (Beckman Coulter).
3 | RESULTS
To determine whether the monkeys became sensitized
to peanut, serum was assessed for both total IgE and
peanut‐specific IgE by ELISA. Some monkeys had
increased IgE during the peanut exposure period; how-
ever, this was not consistent across animals and did not
reach statistical significance (Figure 2A,B). We were
unable to detect peanut‐specific IgE, even at a 1:2
dilution, at any time points in any of the monkeys.
During the oral challenge, none of the monkeys ex-
perienced anaphylaxis as evidenced by a lack of allergic
symptoms and changes in vitals. Histamine levels did
not change relative to their day 32 levels and were not
different than naïve monkeys that were challenged with
peanut, indicating a lack of mast cell degranulation,
consistent with the lack of symptoms and stable vital
signs.
Although peanut‐specific IgE was undetectable, and
monkeys did not experience anaphylaxis upon OFC, we
investigated whether there was any evidence of im-
munogenicity. To do so, we quantified peanut‐specific
IgG throughout the course of peanut exposure via ELISA.
Interestingly, seven of the eight monkeys produced in-
creasing peanut‐specific IgG by day 32 (Figure 2C,D),
with no significant differences between male and female
monkeys (Figure 2C). When all monkeys were combined,
the increase in peanut‐specific IgG at day 32 compared
with the baseline reached statistical significance (P< .05).
These results indicate that repeated exposure to peanut
on the skin is immunogenic.
4 | DISCUSSION
While monkeys did not become sensitized to peanut in the
current model, several limitations could be addressed. Future
studies should investigate longer periods of exposure (eg, 8
weeks instead of 4) and higher doses of peanut in a dose‐
response manner. In addition, the application of peanut to a
disrupted skin barrier has been demonstrated to promote
sensitization in humans,5 which may also be required to
sensitize primates. Interestingly, recent studies from the
LEAP cohort demonstrated that Staphylococcus aureus co-
lonization on the skin was associated with peanut allergy.15
Furthermore, the application site and relative thickness of
the skin may be other important considerations for future
studies. While the 1.2‐ to 1.4‐year‐old monkeys used in this
study are similar in age to when children may develop a
peanut allergy, the use of younger monkeys in future studies
may enable sensitization. Notably, experiments using
monkeys are costly, limited to small sample sizes, and
restricted in terms of procedural capabilities compared with
rodent studies, which limits the number of variables that can
be investigated in a single experiment.
In summary, by adapting a similar protocol to that
used in mice,13 we were unable to detect any peanut‐
specific IgE production postcutaneous peanut exposure,
indicating that this protocol did not sensitize the monkeys
to peanut. Furthermore, monkeys challenged with 200mg
of peanut extract did not experience any allergic symptoms
or detectable histamine release, consistent with a lack of
sensitization. However, these monkeys produced increas-
ing quantities of peanut‐specific IgG throughout the
course of peanut exposure, indicating that the application
of peanut through the skin is immunogenic. Ultimately,
our data do not exclude that monkeys, or humans, can be
sensitized by cutaneous exposure to peanut, we can only
conclude that this particular protocol and study popula-
tion did not become allergic.
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